Aurobindo Pharma Limited
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
What Aurobindo files
- Others79
- Updates76
- Investor Meet65
- Important35
- JV/Acquisition25
- Board Meeting11
Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company
Aurobindo's subsidiary Lannett launched generic Advair Diskus® in the US. This marks their first inhalation product in the US market, expanding Aurobindo's complex respiratory portfolio for asthma and COPD.
Aurobindo Pharma's subsidiary, Apitoria Pharma, concluded its US FDA inspection at Unit-VI, an API manufacturing facility. It resulted in three procedural observations, to which the company will respond promptly.
Aurobindo Pharma's US subsidiary, Lannett Company, concluded a US FDA inspection with four procedural observations. The company will respond promptly, reinforcing its commitment to robust quality and compliance standards.
Aurobindo Pharma's subsidiary, AuroPeptides, completed a US FDA inspection with only one observation regarding facility maintenance. This observation does not relate to data integrity or GMP compliance, and corrective action has been initiated, affirming robust quality standards.